Last reviewed · How we verify

NCT03592732

The Role of Adipokines In Atrial Fibrillation

Status unknown Last updated 1 February 2021
What this trial tests

trial testing Blood sample in Atrial Fibrillation in 100 participants. Status unknown.

Timeline
29 March 2018
Primary endpoint
29 January 2021
29 January 2021

Quick facts

Lead sponsorUniversity of Athens
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date29 March 2018
Primary completion29 January 2021
Estimated completion29 January 2021
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Athens

Who can join

Under 85, any sex, with Atrial Fibrillation or Adiposity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal aim of the present study is to analyze adiponectin, omentin-1, apelin and visfatin plasma levels in patients with and without AF in an effort to identify their potential role in the development of AF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other University of Athens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03592732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing